Cambrex Adds Reactors to Facility in Sweden

Sep 26, 2017
By Pharmaceutical Technology Editors
Volume 12, Issue 10

Cambrex Corporation, a manufacturer of small-molecule innovator and generic APIs, announced the completion of an installation of large-scale manufacturing capacity at its cGMP facility in Karlskoga, Sweden. The expansion included multi-purpose reactors ranging from 4–12-cubic meters in size, and a 9-cubic-meter hydrogenation reactor. The company also announced a multi-year construction project to increase the site’s wastewater processing capabilities in a Sept. 26, 2017 press statement.

The waste water treatment plant, designed to support the expansion and improve existing biological processes, is being phased over a three-year period. The $3.5-million (30.5M SEK) investment will process more than 4000 cubic meters of water daily and handle variations in the composition of effluent. The majority of the construction project will be completed in 2017, with additional upgrades in 2018 and 2019, the company reported, and when completed, the facility will reduce the emission of nitrogen, total organic compounds, and suspended material.

“Our Karlskoga site is a crucial part of the company’s global manufacturing network, and these investments, to not only to increase capacity, but also to the supporting infrastructure, will enable the site to work efficiently both now, and into the future,” commented Bjarne Sandberg, managing director, Cambrex Karlskoga.

The expansion at the company’s Swedish site follows the announcement of the construction of a $24-million, 4500-sq.- ft. highly potent API manufacturing facility at in Charles City, IA, which is due to open in 2019.

Source: Cambrex

 

native1_300x100
lorem ipsum